SGM
MPLT

Seven Grand Managers’s MapLight Therapeutics MPLT Stock Holding History

Seven Grand Managers’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.03M Hold
100,000
– – 0.14% 112
2025
Q4 		$1.76M Buy
+100,000
New +$1.68M 0.13% 114

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Seven Grand Managers's MPLT Position: Q1 2026 in Review

Seven Grand Managers held its MapLight Therapeutics (MPLT) position steady in Q1 2026 at 100,000 shares worth $2.03M. The position accounts for 0.14% of the portfolio, ranked #112.

Seven Grand Managers first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Seven Grand Managers held 100,000 shares of MapLight Therapeutics worth $2.03M as of Q1 2026.
  • Seven Grand Managers left its MapLight Therapeutics share count unchanged in Q1 2026.
  • MapLight Therapeutics made up 0.14% of Seven Grand Managers's portfolio in Q1 2026, its #112 holding.
  • Seven Grand Managers first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Seven Grand Managers's 13F filing for Q1 2026, filed 6 May 2026.